The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease
Open accessAbstract
BACKGROUND AND AIMS: Treatment with infliximab induces remission in about 70% of patients with steroid refractory Crohn's disease. Because Crohn's disease is considered to be mediated by uncontrolled activation of mucosal T lymphocytes, we hypothesised that infliximab could induce apoptosis of T lymphocytes. METHODS: Induction of apoptosis in vivo was studied in 10 patients with therapy refractory Crohn's disease. In vitro, resting or stimulated Jurkat T cells were incubated with infliximab. RESULTS: Infusion of infliximab (5 mg/kg) in steroid refractory patients with Crohn's disease induced a clinical response in 9/10 patients but did not influence expression of activation markers, homing receptors, memory cells, Fas expression, or Bax/Bcl-2 expression on peripheral blood T lymphocytes. In contrast, a significant increase in CD3 and TUNEL positive cells within colonic biopsies was detected 24 hours after infusion of infliximab, suggesting that infliximab stimulates apoptosis of activated T lymphocytes but not of resting T cells. To test this hypothesis, the effects of infliximab on Jurkat T cells were investigated. We observed that infliximab induced apoptosis and an increase in the Bax/Bcl-2 ratio of CD3/CD28 stimulated Jurkat T cells but not of unstimulated Jurkat cells. CONCLUSIONS: Our data indicate that infliximab treatment causes a rapid and specific increase in apoptosis of T lymphocytes in the gut mucosa. These findings may explain the rapid and sustained therapeutic effects of infliximab in Crohn's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death
Oltval, Z. N., Milliman, C. L., & Korsmeyer, S. J. (1993) · Cell · doi:10.1016/0092-8674(93)90509-o · Cited by 6,003
The Bcl-2 Protein Family: Arbiters of Cell Survival
Adams, J. M., & Cory, S. (1998) · Science · doi:10.1126/science.281.5381.1322 · Cited by 5,332
Targan, S. R., Hanauer, S. B., van Deventer, S. J. H., Mayer, L., Present, D. H., Braakman, T., DeWoody, K. L., Schaible, T. F., & Rutgeerts, P. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710093371502 · Cited by 3,135
Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease
Present, D. H., Rutgeerts, P., Targan, S., Hanauer, S. B., Mayer, L., van Hogezand, R. A., Podolsky, D. K., Sands, B. E., Braakman, T., DeWoody, K. L., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905063401804 · Cited by 2,752
Weinblatt, M. E., Kremer, J. M., Bankhurst, A. D., Bulpitt, K. J., Fleischmann, R. M., Fox, R. I., Jackson, C. G., Lange, M., & Burge, D. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901283400401 · Cited by 2,085
The proto-oncogene Bcl-2 and its role in regulating apoptosis
Kroemer, G. (1997) · Nature Medicine · doi:10.1038/nm0697-614 · Cited by 1,739
Experimental models of inflammatory bowel disease
Elson, C. O., Sartor, R. B., Tennyson, G. S., & Riddell, R. H. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90599-5 · Cited by 1,212
Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)
van Dullemen, H. M., van Deventer, S. J. H., Hommes, D. W., Bijl, H. A., Jansen, J., Tytgat, G. N. J., & Woody, J. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90277-5 · Cited by 1,084
Homeostasis and Self-Tolerance in the Immune System: Turning Lymphocytes off
Parijs, L. V., & Abbas, A. K. (1998) · Science · doi:10.1126/science.280.5361.243 · Cited by 965
D'Haens, G., Van Deventer, S., Van Hogezand, R., Chalmers, D., Kothe, C., Baert, F., Braakman, T., Schaible, T., Geboes, K., & Rutgeerts, P. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70005-3 · Cited by 745
Cited by
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
Rutgeerts, P., Sandborn, W. J., Feagan, B. G., Reinisch, W., Olson, A., Johanns, J., Travers, S., Rachmilewitz, D., Hanauer, S. B., Lichtenstein, G. R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050516 · Cited by 3,902
Podolsky, D. K. (2002) · New England Journal of Medicine · doi:10.1056/nejmra020831 · Cited by 3,159
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
Colombel, J. F., Sandborn, W. J., Reinisch, W., Mantzaris, G. J., Kornbluth, A., Rachmilewitz, D., Lichtiger, S., D'Haens, G., Diamond, R. H., Broussard, D. L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0904492 · Cited by 3,143
Cytokines in inflammatory bowel disease
Neurath, M. F. (2014) · Nature Reviews Immunology · doi:10.1038/nri3661 · Cited by 2,706
Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitis
Sartor, R. B. (2006) · Nature Clinical Practice Gastroenterology & Hepatology · doi:10.1038/ncpgasthep0528 · Cited by 1,757
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
Tracey, D., Klareskog, L., Sasso, E. H., Salfeld, J. G., & Tak, P. P. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.10.001 · Cited by 1,628
Immunopathogenesis of IBD: current state of the art
de Souza, H. S. P., & Fiocchi, C. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.186 · Cited by 1,551
Granulomatous Infectious Diseases Associated with Tumor Necrosis Factor Antagonists
Wallis, R. S., Broder, M. S., Wong, J. Y., Hanson, M. E., & Beenhouwer, D. O. (2004) · Clinical Infectious Diseases · doi:10.1086/383317 · Cited by 977
Interleukin-18 and IL-18 Binding Protein
Dinarello, C. A., Novick, D., Kim, S., & Kaplanski, G. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00289 · Cited by 938
“The induction of fever, a well-studied property of IL-1α and IL-1β as well as acute phase proteins, TNFα and IL-6, is not a significant property of IL-18.”
BackgroundInfluentialTransmembrane TNF- : structure, function and interaction with anti-TNF agents
Horiuchi, T., Mitoma, H., Harashima, S.-I., Tsukamoto, H., & Shimoda, T. (2010) · Rheumatology · doi:10.1093/rheumatology/keq031 · Cited by 864
Van den Brande, J. M. H., Braat, H., van den Brink, G. R., Versteeg, H. H., Bauer, C. A., Hoedemaeker, I., van Montfrans, C., Hommes, D. W., Peppelenbosch, M. P., & van Deventer, S. J. H. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00382-2 · Cited by 723
Solovic, I., Sester, M., Gomez-Reino, J. J., Rieder, H. L., Ehlers, S., Milburn, H. J., Kampmann, B., Hellmich, B., Groves, R., Schreiber, S., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00028510 · Cited by 527
Nesbitt, A., Fossati, G., Bergin, M., Stephens, P., Stephens, S., Foulkes, R., Brown, D., Robinson, M., & Bourne, T. (2007) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20225 · Cited by 477
Perera, G. K., Di Meglio, P., & Nestle, F. O. (2012) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011811-132448 · Cited by 462
Optimizing anti-TNF treatment in inflammatory bowel disease
Rutgeerts, P., van Assche, G., & Vermeire, S. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.02.070 · Cited by 429
Latent tuberculosis: mechanisms of host and bacillus that contribute to persistent infection
Tufariello, J. M., Chan, J., & Flynn, J. L. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00741-2 · Cited by 403
Waetzig, G. H., Seegert, D., Rosenstiel, P., Nikolaus, S., & Schreiber, S. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.10.5342 · Cited by 395
Atreya, R., Neumann, H., Neufert, C., Waldner, M. J., Billmeier, U., Zopf, Y., Willma, M., App, C., Münster, T., Kessler, H., et al. (2014) · Nature Medicine · doi:10.1038/nm.3462 · Cited by 392
Slifman, N. R., Gershon, S. K., Lee, J., Edwards, E. T., & Braun, M. M. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10758 · Cited by 383
Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics
Feldmann, M., & Maini, S. R. N. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00626.x · Cited by 381
Probert, C. S. J., Hearing, S. D., Schreiber, S., Kühbacher, T., Ghosh, S., Arnott, I. D. R., & Forbes, A. (2003) · Gut · doi:10.1136/gut.52.7.998 · Cited by 355
Mechanism of Action of Anti-TNF Therapy in Inflammatory Bowel Disease
Levin, A. D., Wildenberg, M. E., & van den Brink, G. R. (2016) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjw053 · Cited by 336
Fungal Infections Complicating Tumor Necrosis Factor α Blockade Therapy
Tsiodras, S., Samonis, G., Boumpas, D. T., & Kontoyiannis, D. P. (2008) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60839-2 · Cited by 331
Molecular mechanisms of action of anti-TNF-α agents – Comparison among therapeutic TNF-α antagonists
Mitoma, H., Horiuchi, T., Tsukamoto, H., & Ueda, N. (2018) · Cytokine · doi:10.1016/j.cyto.2016.08.014 · Cited by 316
TNFα blockade in human diseases: Mechanisms and future directions
Wong, M., Ziring, D., Korin, Y., Desai, S., Kim, S., Lin, J., Gjertson, D., Braun, J., Reed, E., & Singh, R. R. (2008) · Clinical Immunology · doi:10.1016/j.clim.2007.08.013 · Cited by 307
Zeissig, S., Bojarski, C., Buergel, N., Mankertz, J., Zeitz, M., Fromm, M., & Schulzke, J. D. (2004) · Gut · doi:10.1136/gut.2003.036632 · Cited by 305
Eissner, G., Kolch, W., & Scheurich, P. (2004) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2004.03.011 · Cited by 298
How tumour necrosis factor blockers interfere with tuberculosis immunity
Harris, J., & Keane, J. (2010) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2010.04146.x · Cited by 291
An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab
Wyant, T., Fedyk, E., & Abhyankar, B. (2016) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjw092 · Cited by 284
Interleukin-18, more than a Th1 cytokine
Novick, D., Kim, S., Kaplanski, G., & Dinarello, C. A. (2013) · Seminars in Immunology · doi:10.1016/j.smim.2013.10.014 · Cited by 280
Tumour necrosis factor antagonists: structure, function, and tuberculosis risks
Wallis, R. S. (2008) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(08)70227-5 · Cited by 275
Anti-TNF Therapy in Crohn’s Disease
Adegbola, S. O., Sahnan, K., Warusavitarne, J., Hart, A., & Tozer, P. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082244 · Cited by 274
Averting inflammation by targeting the cytokine environment
Kopf, M., Bachmann, M. F., & Marsland, B. J. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2805 · Cited by 257
Atreya, R., Zimmer, M., Bartsch, B., Waldner, M. J., Atreya, I., Neumann, H., Hildner, K., Hoffman, A., Kiesslich, R., Rink, A. D., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.08.032 · Cited by 256
Galectin-1 suppresses experimental colitis in mice
Santucci, L., Fiorucci, S., Rubinstein, N., Mencarelli, A., Palazzetti, B., Federici, B., Rabinovich, G. A., & Morelli, A. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00267-1 · Cited by 256
Catrina, A. I., Trollmo, C., af Klint, E., Engstrom, M., Lampa, J., Hermansson, Y., Klareskog, L., & Ulfgren, A. K. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20764 · Cited by 255
Recent understanding of IBD pathogenesis: Implications for future therapies
Kucharzik, T., Maaser, C., Lügering, A., Kagnoff, M., Mayer, L., Targan, S., & Domschke, W. (2006) · Inflammatory Bowel Diseases · doi:10.1097/01.mib.0000235827.21778.d5 · Cited by 254
Clark, M., Colombel, J.-F., Feagan, B. C., Fedorak, R. N., Hanauer, S. B., Kamm, M. A., Mayer, L., Regueiro, C., Rutgeerts, P., Sandborn, W. J., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.05.006 · Cited by 224
Human γδ T-Cell Control of Mucosal Immunity and Inflammation
McCarthy, N. E., & Eberl, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00985 · Cited by 96
Metadata
- Authors
- ten Hove, T.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2002-02-01
- Volume
- 50
- Issue
- 2
- Pages
- 206-211
- ISSN
- 0017-5749 (ISSN-L)
- OpenAlex
- W1922746363
- Cited by
- 545
- References
- 37
- FWCI
- 28.35
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.